BR112023020659A2 - Métodos para controlar a atividade de célula imune - Google Patents
Métodos para controlar a atividade de célula imuneInfo
- Publication number
- BR112023020659A2 BR112023020659A2 BR112023020659A BR112023020659A BR112023020659A2 BR 112023020659 A2 BR112023020659 A2 BR 112023020659A2 BR 112023020659 A BR112023020659 A BR 112023020659A BR 112023020659 A BR112023020659 A BR 112023020659A BR 112023020659 A2 BR112023020659 A2 BR 112023020659A2
- Authority
- BR
- Brazil
- Prior art keywords
- cellular immunotherapy
- methods
- target antigen
- immune cell
- individual
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021901030A AU2021901030A0 (en) | 2021-04-08 | Methods for controlling immune cell activity | |
| PCT/AU2022/050311 WO2022213154A1 (en) | 2021-04-08 | 2022-04-08 | Methods for controlling immune cell activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023020659A2 true BR112023020659A2 (pt) | 2023-12-05 |
Family
ID=83544929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023020659A BR112023020659A2 (pt) | 2021-04-08 | 2022-04-08 | Métodos para controlar a atividade de célula imune |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250282844A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4319793A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024513485A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117157092A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022253547A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023020659A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3213042A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023011807A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022213154A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026507807A (ja) * | 2023-03-08 | 2026-03-06 | バイオセプター (オースト) プロプライエタリー・リミテッド | 機能不全p2x7受容体に結合するためのキメラ抗原受容体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101555283B (zh) * | 2001-01-17 | 2012-03-21 | 生物权威国际有限公司 | 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途 |
| WO2003020762A1 (en) * | 2001-09-03 | 2003-03-13 | Intreat Pty Limited | Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions |
| AU2009266430B2 (en) * | 2008-07-04 | 2014-08-14 | Biosceptre International Limited | Anti- P2X7 peptides and epitopes |
| ES2699753T3 (es) * | 2014-01-29 | 2019-02-12 | Biontech Ag | Mimótopos peptídicos de claudina 18.2 y sus usos |
| EP3484455A2 (en) * | 2016-07-15 | 2019-05-22 | Novartis AG | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
| US10986601B2 (en) * | 2017-07-26 | 2021-04-20 | Panoramic Power Ltd. | System and method for timing synchronization of a self-powered power sensor |
| CA3211323A1 (en) * | 2021-03-11 | 2022-09-15 | Patrick Schlegel | Novel cell therapy system |
-
2022
- 2022-04-08 BR BR112023020659A patent/BR112023020659A2/pt unknown
- 2022-04-08 AU AU2022253547A patent/AU2022253547A1/en active Pending
- 2022-04-08 JP JP2023561706A patent/JP2024513485A/ja active Pending
- 2022-04-08 EP EP22783698.8A patent/EP4319793A4/en active Pending
- 2022-04-08 CA CA3213042A patent/CA3213042A1/en active Pending
- 2022-04-08 MX MX2023011807A patent/MX2023011807A/es unknown
- 2022-04-08 CN CN202280026923.7A patent/CN117157092A/zh active Pending
- 2022-04-08 WO PCT/AU2022/050311 patent/WO2022213154A1/en not_active Ceased
- 2022-04-08 US US18/285,621 patent/US20250282844A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022213154A1 (en) | 2022-10-13 |
| US20250282844A1 (en) | 2025-09-11 |
| EP4319793A4 (en) | 2025-03-19 |
| MX2023011807A (es) | 2024-01-05 |
| AU2022253547A1 (en) | 2023-10-05 |
| JP2024513485A (ja) | 2024-03-25 |
| CA3213042A1 (en) | 2022-10-13 |
| CN117157092A (zh) | 2023-12-01 |
| EP4319793A1 (en) | 2024-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022020256A2 (pt) | anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo | |
| BR112022015374A2 (pt) | Anticorpos contra sars-cov-2 e métodos de uso dos mesmos | |
| BRPI0413314A (pt) | antìgeno quimérico para provocar uma resposta imune, métodos para realçar a apresentação de antìgeno em uma célula que apresenta antìgeno, para ativar uma célula que apresenta antìgeno, para provocar uma resposta imune, para quebrar a toleráncia, e para tratar uma condição imuno-tratável, composição farmacêutica, artigo de fabricação, método para produzir um antìgeno quimérico, polinucleotìdeo, microorganismo ou linhagem celular, e, vetor | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| BRPI0812913B8 (pt) | anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos | |
| BRPI0507433B8 (pt) | anticorpo monoclonal recombinante ou sua parte de ligação ao antígeno, composição, ácido nucleico isolado, vetor de expressão, e, kit | |
| BR112022020706A2 (pt) | Anticorpos contra sars-cov-2 e métodos de uso dos mesmos | |
| BR112021024553A2 (pt) | Molécula de ligação específica para cd73 e uso de molécula de ligação | |
| WO2018170338A3 (en) | High affinity mage-a1-specific tcrs and uses thereof | |
| MX2021007947A (es) | Terapeuticos de anticuerpo que se unen a ctla4. | |
| MX2021011633A (es) | Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn. | |
| EP3812398A3 (en) | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 | |
| BR112017018770A2 (pt) | redução da tolerância imunológica induzida por pd-l1 | |
| PT1819830E (pt) | Métodos para engenharia de anticorpos | |
| BR112012017124C1 (pt) | Método para produzir e para purificar um multímero polipeptídico | |
| BR112012012912A2 (pt) | anticorpo ou fragmento do mesmo, ácido nucleico, vetor, célula hospedeira, método para a produção de um anticorpo ou um fragmento do mesmo, composição farmacêutica, método para tratar ou prevenir uma condição médica em um indivíduo, uso de um anticorpo ou fragmento do mesmo e métodos in vitro para neutralizar il-10 em uma amostra e para detectar a presença de il-10 em uma amostra. | |
| NO20090069L (no) | Malrettede forbindelser rettet mot binding til PDGFR-alfa og deres anvendelse | |
| BR112021021281A2 (pt) | Anticorpo monoclonal que se liga especificamente ao gitr | |
| ZA202201464B (en) | Anti-tigit antibodies and application thereof | |
| NZ785401A (en) | Anti-ms4a4a antibodies and methods of use thereof | |
| WO2022032003A3 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| BRPI0606790A2 (pt) | anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna. | |
| WO2023205186A3 (en) | Dna therapeutic encoding an antibody or antigen binding fragment | |
| BR112022000216A2 (pt) | Anticorpos direcionados a dll3 e usos dos mesmos | |
| WO2020076789A3 (en) | Combinations of anti-staphylococcus aureus antibodies |